98%
921
2 minutes
20
Background: Atopic dermatitis is the most common inflammatory skin disease in childhood and has an important impact on quality of life, especially severe cases or those that are recalcitrant to treatments. Sensitization to allergens with the potential for allergic contact dermatitis is a factor associated with cases of recalcitrant atopic dermatitis. Understanding the relationship between atopic dermatitis, allergens, and allergic contact dermatitis is essential. In Brazil, there are no studies on sensitization to allergens found in patch tests with pediatric batteries in patients with atopic dermatitis.
Objectives: To verify the main sensitizing agents, the prevalence of allergic contact dermatitis and the epidemiological and clinical profile of children and adolescents with atopic dermatitis.
Methods: Cross-sectional, prospective study in patients between 4 and 18 years of age, with recalcitrant atopic dermatitis, treated at the Sanitary Dermatology Outpatient Clinic (RS). All patients underwent patch tests with a battery of pediatric allergens.
Results: The prevalence of sensitization and allergic contact dermatitis in the evaluated patients was 37.07% (20/54) and 27.7% (15/54), respectively. The most frequent allergens were: nickel sulfate (16.7%), disperse blue (5.6%), and fragrance mix I (5.6%). Nickel was associated with the female sex (p = 0.019).
Study Limitations: Sample size and selection, absence of a control group.
Conclusions: A proportion of patients with recalcitrant atopic dermatitis may be sensitized to different allergens and may even have developed allergic contact dermatitis. Recognizing this context is important in the prevention strategy and management of the disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133262 | PMC |
http://dx.doi.org/10.1016/j.abd.2021.08.005 | DOI Listing |
Pediatr Dermatol
September 2025
Harvard Medical School, Boston, Massachusetts, USA.
Background/objectives: Children with atopic dermatitis (AD) frequently experience sleep disturbances. Melatonin, an over-the-counter supplement, is increasingly used in the general pediatric population; however, its prevalence and perceived effectiveness in children with AD remain unclear.
Methods: Caregivers of pediatric patients (ages 1-17 years) with physician-diagnosed AD completed surveys on melatonin use, Patient Oriented Eczema Measure (POEM), and age-appropriate sleep questionnaires.
Arch Pharm Res
September 2025
College of Pharmacy and Medical Research Center, Chungbuk National University, 194-21, Osongsaengmyeong 1-ro, Osong-eup, Cheongju-si, Chungcheongbuk-do, 28160, Republic of Korea.
Atopic dermatitis (AD) is an inflammatory skin disease that produces a variety of inflammatory cytokines and chemokines. Chitinase-3-like protein 1 (CHI3L1, YKL-40) significantly contributes to AD-associated inflammatory response and is highly expressed in patients with AD. Therefore, this study elucidated the effects and potential mechanisms of human YKL-40 antibody on AD-affected skin.
View Article and Find Full Text PDFJ Cutan Med Surg
September 2025
FACET Dermatology, Toronto, ON, Canada.
Allergol Immunopathol (Madr)
September 2025
Inflamm-Aging Translational Research Center, Ajou University Medical Center, Suwon, Republic of Korea;
Thunberg is a perennial herbaceous plant of the genus that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages.
View Article and Find Full Text PDFCureus
August 2025
Department of Dermatology, Poznan University of Medical Sciences, Poznan, POL.
Atopic dermatitis (AD) is a chronic inflammatory skin condition often complicated by cardiovascular comorbidities, impacting treatment options and outcomes. In this paper, we present a 41-year-old patient with severe AD, asthma, and chronic heart failure, who responded well to dupilumab, showing significant improvements in skin severity scores and heart function. This case underscores the effectiveness of dupilumab in managing AD alongside complex comorbidities.
View Article and Find Full Text PDF